National findings from the Tracks survey of people who inject drugs in Canada, Phase 4, 2017-2019.

HIV care and treatment drug use hepatitis C infection status injecting behaviours overdose people who inject drugs sexual risk practices testing

Journal

Canada communicable disease report = Releve des maladies transmissibles au Canada
ISSN: 1188-4169
Titre abrégé: Can Commun Dis Rep
Pays: Canada
ID NLM: 9303729

Informations de publication

Date de publication:
07 May 2020
Historique:
entrez: 14 3 2022
pubmed: 7 5 2020
medline: 7 5 2020
Statut: epublish

Résumé

The Tracks survey of people who inject drugs (PWID) collected data in 14 sentinel sites across Canada (2017-2019). To describe the prevalence of human immunodeficiency virus (HIV) and hepatitis C and associated risk behaviours and to examine trends over time. Information regarding socio-demographics, social determinants of health, use of prevention services and testing, drug use, risk behaviours, and HIV and hepatitis C testing, care and treatment was collected through interviewer-administered questionnaires. Biological samples were tested for HIV, hepatitis C antibodies and hepatitis C ribonucleic acid (RNA). Descriptive statistics were calculated and trends over time were assessed. Of the 2,383 participants, 65.6% were cisgender male, 42.2% were Indigenous, 48.0% completed some high school or less, 62.6% lived in unstable housing and 75.7% had ever been incarcerated. Average age was 40.1 years. The majority experienced stigma and discrimination (88.7%) and physical, sexual and/or emotional abuse in childhood (85.0%) or with a sexual partner (75.9%). The majority reported use of a needle/syringe distribution program (90.1%) and tested for HIV (90.5%) and hepatitis C (90.9%).Among participants who had ever had sex, the majority (59.2%) reported inconsistent condom use during vaginal and/or anal sex with a casual sex partner. Prevalence of HIV was 10.3% (82.9% were aware of infection status) and many (36.9%) were hepatitis C RNA-positive (50.1% were aware of infection status).Most surveillance indicators remained relatively stable from Phase 1 to Phase 4. Changes were found in substances used, and improvements were noted related to HIV and hepatitis C prevalence and care cascade indicators. Many PWID in Canada were living in unstable housing and experienced high levels of stigma and discrimination. Prevalence of HIV and hepatitis C was high in some areas. These findings contribute to the evidence base used to inform targeted prevention and control measures.

Sections du résumé

Background UNASSIGNED
The Tracks survey of people who inject drugs (PWID) collected data in 14 sentinel sites across Canada (2017-2019).
Objective UNASSIGNED
To describe the prevalence of human immunodeficiency virus (HIV) and hepatitis C and associated risk behaviours and to examine trends over time.
Methods UNASSIGNED
Information regarding socio-demographics, social determinants of health, use of prevention services and testing, drug use, risk behaviours, and HIV and hepatitis C testing, care and treatment was collected through interviewer-administered questionnaires. Biological samples were tested for HIV, hepatitis C antibodies and hepatitis C ribonucleic acid (RNA). Descriptive statistics were calculated and trends over time were assessed.
Results UNASSIGNED
Of the 2,383 participants, 65.6% were cisgender male, 42.2% were Indigenous, 48.0% completed some high school or less, 62.6% lived in unstable housing and 75.7% had ever been incarcerated. Average age was 40.1 years. The majority experienced stigma and discrimination (88.7%) and physical, sexual and/or emotional abuse in childhood (85.0%) or with a sexual partner (75.9%). The majority reported use of a needle/syringe distribution program (90.1%) and tested for HIV (90.5%) and hepatitis C (90.9%).Among participants who had ever had sex, the majority (59.2%) reported inconsistent condom use during vaginal and/or anal sex with a casual sex partner. Prevalence of HIV was 10.3% (82.9% were aware of infection status) and many (36.9%) were hepatitis C RNA-positive (50.1% were aware of infection status).Most surveillance indicators remained relatively stable from Phase 1 to Phase 4. Changes were found in substances used, and improvements were noted related to HIV and hepatitis C prevalence and care cascade indicators.
Conclusion UNASSIGNED
Many PWID in Canada were living in unstable housing and experienced high levels of stigma and discrimination. Prevalence of HIV and hepatitis C was high in some areas. These findings contribute to the evidence base used to inform targeted prevention and control measures.

Identifiants

pubmed: 35283692
doi: 10.14745/ccdr.v46i05a07
pii: 460507
pmc: PMC8868043
doi:

Types de publication

Journal Article

Langues

eng

Pagination

138-148

Déclaration de conflit d'intérêts

Conflict of interest: None.

Références

CMAJ. 2011 Jul 12;183(10):1147-54
pubmed: 21670106
Lancet Infect Dis. 2016 Dec;16(12):1385-1398
pubmed: 27665254
Liver Int. 2019 Aug;39(8):1400-1407
pubmed: 30653809
Addiction. 2019 Dec;114(12):2173-2186
pubmed: 31328354

Auteurs

Jill Tarasuk (J)

Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON.

Jingxuan Zhang (J)

Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON.

Anaïs Lemyre (A)

Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON.

François Cholette (F)

National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB.

Maggie Bryson (M)

Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON.

Dana Paquette (D)

Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON.

Classifications MeSH